Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda

PURPOSEPatients with diffuse large B-cell lymphoma (DLBCL) who are treated in low-resource settings have inferior outcomes compared with those in high-resource settings. Rituximab, an anti-CD20 monoclonal antibody, when combined with chemotherapy, improves overall survival (OS) for DLBCL. However, i...

Full description

Saved in:
Bibliographic Details
Main Authors: Manoj P. Menon, Henry Ddungu, Kelvin R. Mubiru, Scott V. Adams, Jacqueline Asea, Rosemary Namagembe, Prossy Namuli, Joyce Kambugu, Andrea M.H. Towlerton, Camille Puronen, Thomas S. Uldrick, Jackson Orem, Edus H. Warren
Format: Article
Language:English
Published: American Society of Clinical Oncology 2025-04-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO-24-00489
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://ascopubs.org/doi/10.1200/GO-24-00489

Similar Items